Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
Department of Pathology, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia.
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2843-2845.e2. doi: 10.1016/j.cgh.2019.09.027. Epub 2019 Sep 28.
Because only a minority of patients with nonalcoholic fatty liver disease (NAFLD) have advanced fibrosis and would eventually develop liver-related complications, current guidelines recommend initial assessment with noninvasive tests of fibrosis. Most previous studies focused on overweight and obese patients. Despite a strong association between obesity and NAFLD, 3%-30% of people with relatively normal body mass index (BMI) may still have NAFLD. Hence, this study aims to evaluate the performance of the common noninvasive tests in non-obese (BMI <25 kg/m) and obese (BMI ≥25 kg/m) NAFLD patients.
由于只有少数非酒精性脂肪性肝病（NAFLD）患者有进展性肝纤维化，并最终会出现与肝脏相关的并发症，因此目前的指南建议采用非侵入性的肝纤维化检测方法进行初步评估。大多数先前的研究都集中在超重和肥胖患者上。尽管肥胖与 NAFLD 之间存在很强的关联，但仍有 3%-30%的体重指数（BMI）相对正常的人群可能患有 NAFLD。因此，本研究旨在评估常见非侵入性检测方法在非肥胖（BMI<25kg/m）和肥胖（BMI≥25kg/m）NAFLD 患者中的性能。
